BrandonGeorgeSmagloMDFACP

PubMed

• 14 citations
  Impact of KRAS mutations and co-mutations on clinical outcomes in pancreatic ductal adenocarcinoma.
  Abdelrahman Yousef, Mahmoud Yousef, Saikat Chowdhury, Kawther Abdilleh, Mark Knafl
  NPJ Precision Oncology. 2024-02-03
• 2 citations
  Addition of Metastasis-Directed Therapy to Systemic Therapy for Oligometastatic Pancreatic Ductal Adenocarcinoma (EXTEND): A Multicenter, Randomized Phase II Trial.
  Ethan B Ludmir, Alexander D Sherry, Bryan M Fellman, Suyu Liu, Tharakeswara Bathala
  Journal of Clinical Oncology. 2024-11-10
• 12 citations
  Efficacy of pembrolizumab in patients with advanced cancer of unknown primary (CUP): a phase 2 non-randomized clinical trial.
  Kanwal P Raghav, Bettzy Stephen, Daniel D Karp, Sarina A Piha-Paul, David S Hong
  Journal for Immunotherapy of Cancer. 2022-05-01

Lectures

• Targeting pancreatic cancer using nonengineered, multiantigen specific T cells (TACTOPS) 
  AACR Immune Cell Therapies for Cancer meeting, San Francisco, CA - 7/20/2019
• Neoadjuvant Chemotherapy Alone Versus Neoadjuvant Chemoradiation Therapy for Locally Advanced Esophageal Cancer -AND- Who Benefits from Adjuvant Therapy following Neoa... 
  Current Medical and Surgical Management of Esophageal Diseases Meeting
• State-of-the-Art Medical Management of Colorectal Cancer 
  Baylor St Luke’s Medical Center Oncology Grand Rounds, - 3/20/2017
• Is there an optimal treatment sequence in the palliative management of mCRC? 
  The 12th Annual Meeting of the International Society of Gastrointestinal Oncology, - 10/2015
• Targeted Therapy for Resectable GIST 
  Medstar Georgetown University Hospital Second Annual Symposium on GIST - 9/12/2015
• Systemic Therapy for Gastric Cancer 
  The 11thAnnual Georgetown Meeting on GastroIntestinal Endoscopy, Foregut & Pancreatobiliary Surgery - 3/7/2015
• Adjuvant Therapy for Resectable GIST 
  Medstar Georgetown University Hospital First Annual Symposium on GIST - 5/10/2014
• Join now to see all